Related Experiment Video
Updated: Mar 19, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies
L T Zane1, S Chanda1, K Jarnagin1
1Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA, USA.
Abstract:
Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease that is characterized by intense pruritus and eczematous lesions with up to 90% of patients presenting with mild to moderate disease. Current topical treatments for AD have not changed in over 15 years and are associated with safety concerns. In AD, overactivity of phosphodiesterase 4 (PDE4), leads to inflammation and disease exacerbation. Crisaborole Topical Ointment, 2%, is a novel, nonsteroidal, topical anti-inflammatory PDE4 inhibitor currently being investigated for the treatment of mild to moderate AD. Preliminary studies in children and adults demonstrated favorable efficacy and safety profiles. Crisaborole may represent an anti-inflammatory option that safely minimizes the symptoms and severity of AD and that can be used for both acute and long-term management.
More Related Videos
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
06:47Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
Related Concept Videos
Clinical Trials: Overview
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Preclinical Development: Overview
Acne Infection